comprehensive -WSS

comprehensive

author：fashion 2025-09-29 01:35:54 - browse：2225

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Melinda French Gates resigns from Gates Foundation

hotspot

knowledge

WSS

UnitedHealth financials solid despite Change Healthcare cyberattack

Skip the lead apron during X

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Skip the lead apron during X

Security flaws in third

Drug cartel violence flares in western Mexico after vigilante leader's killing

explore

comprehensive

focus

Hepatitis C has a cure — but many Americans still lack access to it

Bird flu in milk supply is likely coming from asymptomatic cows

Alkermes shareholders re

Dexcom's push to bring CGM to type 2 diabetes patients

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The wait for US passports is creating travel purgatory and snarling summer plans

Apple is now the first public company to be valued at $3 trillion

H5N1 bird flu virus started spreading in cows in Texas in December

Activists slam private health insurers over coverage restrictions

Key Senate committee drafts bipartisan bill to stem drug shortages

explore

'Screen and refer' systems are hurting patients

MultiPlan and major insurers sued for alleged medical price

Q&A: Jennifer Adair on making gene therapy available globally

Skip the lead apron during X

Close Medicare's dangerous gaps in addiction treatment coverage

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

hotspot

explore

knowledge

explore